Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Praxis Precision Medicines, Inc.PRAX · Entity 3538 | Chief Medical Officer | June 22, 2022 | June 24, 2022 |
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | Chief Medical Officer | April 10, 2018 | April 12, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Praxis Precision Medicines, Inc.
Report date June 22, 2022 · Filed June 24, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.12 · Expires 2032-06-22 | Direct | 65,000 |
Reported balance
After 2022-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-22 · Grant · Acquired 65,000 · Balance 65,000 F1: The shares underlying this stock option vest over a four-year period, with 25% vesting on June 22, 2023 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this stock option vest over a four-year period, with 25% vesting on June 22, 2023 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date.
Voyager Therapeutics, Inc.
Report date April 10, 2018 · Filed April 12, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-04-10 transaction · row 1
1 source rowRow 1 · 2018-04-10 · Sale · Disposed 2,451 · Balance 0 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.04 to $18.61, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.04 to $18.61, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2022 Filed Jun 24, 2022 20:47 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001689548-22-000091 · wf-form4_165610361036996.xml · derivative · entry 1 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2032-06-22 F1 · derivative.exercise_date: The shares underlying this stock option vest over a four-year period, with 25% vesting on June 22, 2023 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date. Read SEC document |
| February 12, 2022 Filed Feb 16, 2022 00:38 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | Tax withholdingCommon Stock | 3,057 | $12.85 | $39,282.45 |
DisclosureSEC source: 0001689548-22-000007 · wf-form4_164497188813645.xml · nonDerivative · entry 1 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,476 F1 · kind: Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported Restricted Share Units. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:08 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 77,000 | $0.00 Strike: $18.11 | $0.00 |
DisclosureSEC source: 0001104659-22-003162 · tm222494-4_4seq1.xml · derivative · entry 2 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2032-01-07 F2 · derivative.exercise_date: The shares underlying this stock option vest over a four-year period, with 25% vesting on January 7, 2023 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:08 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantCommon Stock | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-003162 · tm222494-4_4seq1.xml · nonDerivative · entry 1 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,533 F1 · shares: Dr. Ravina was awarded 22,000 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units vest in equal annual installments over a four-year period beginning on January 7, 2023, subject to the reporting person's continued service through each vesting date. The restricted stock units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:55 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 65,800 | $0.00 Strike: $52.53 | $0.00 |
DisclosureSEC source: 0001689548-21-000009 · wf-form4_161359890175184.xml · derivative · entry 2 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,800 Underlying: Common Stock · 65,800 shares Expires 2031-02-12 F2 · derivative.exercise_date: The shares underlying this stock option vest over a four-year period, with 25% vesting on the one-year anniversary of the vesting commencement date of February 12, 2021 and the remaining 75% vesting in 36 equal monthly installments following such first anniversary, subject to the reporting person's continued service through each vesting date. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:55 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantCommon Stock | 24,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001689548-21-000009 · wf-form4_161359890175184.xml · nonDerivative · entry 1 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,533 F1 · shares: Dr. Ravina was awarded 24,512 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units vest over a four-year period, with 10,412 shares vesting on February 12, 2022, 4,700 shares vesting on February 12, 2023, 4,700 shares vesting on February 12, 2024 and 4,700 shares vesting on February 12, 2025. The restricted stock units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 00:13 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,000 | $2.27 Strike: $2.27 | $102,150.00 |
DisclosureSEC source: 0001628280-21-000107 · wf-form4_160989198758164.xml · derivative · entry 2 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,479 Underlying: Common Stock · 45,000 shares Expires 2028-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of this option vested and became exercisable on August 21, 2019, with the remainder vesting in 36 equal monthly installments thereafter. This option was initially for 195,500 shares and the Reporting Person has exercised his option to purchase 56,021 shares since such grant date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 00:13 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | Exercise / conversionCommon Stock | 45,000 | $2.27 | $102,150.00 |
DisclosureSEC source: 0001628280-21-000107 · wf-form4_160989198758164.xml · nonDerivative · entry 1 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 10, 2018 Filed Apr 12, 2018 20:01 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 2,451 | $18.38 | $45,049.38 |
DisclosureSEC source: 0001104659-18-023708 · a4.xml · nonDerivative · entry 1 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.04 to $18.61, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 20:07 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 2,451 | $25.16 | $61,667.16 |
DisclosureSEC source: 0001104659-18-017480 · a4.xml · nonDerivative · entry 1 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,451 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 00:11 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $28.72 | $0.00 |
DisclosureSEC source: 0001104659-18-016414 · a4.xml · derivative · entry 1 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2028-03-07 F1 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of the Vesting Commencement Date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| February 12, 2018 Filed Feb 13, 2018 21:10 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 2,451 | $18.24 | $44,706.24 |
DisclosureSEC source: 0001104659-18-009011 · a4.xml · nonDerivative · entry 1 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,902 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 10, 2018 Filed Jan 12, 2018 13:57 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 3,630 | $16.40 | $59,532.00 |
DisclosureSEC source: 0001104659-18-001967 · a4.xml · nonDerivative · entry 1 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,353 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 21:02 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 5,490 | $13.63 | $74,828.70 |
DisclosureSEC source: 0001104659-17-073124 · a4.xml · nonDerivative · entry 1 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,983 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.32 to $14.03, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| November 10, 2017 Filed Nov 13, 2017 21:15 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 5,490 | $13.26 | $72,797.40 |
DisclosureSEC source: 0001104659-17-067963 · a4.xml · nonDerivative · entry 1 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,473 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.50, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 23:28 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 10,980 | $20.33 | $223,223.40 |
DisclosureSEC source: 0001104659-17-062001 · a4.xml · nonDerivative · entry 1 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,963 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.93 to $20.49, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 21:23 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 10,980 | $14.30 | $157,014.00 |
DisclosureSEC source: 0001104659-17-056988 · a4.xml · nonDerivative · entry 2 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,943 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.95, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4. F3 · balance_after: This total reflects an adjustment for a clerical error on the reporting person's Form 3 wherein the number of shares beneficially owned was inadvertently overstated by 62,744 shares. Such shares were sold prior to Dr. Ravina becoming a reporting person. F5 · balance_after: This total reflects the number of shares beneficially owned by the reporting person as of the date hereof, following the reported transaction and inclusive of all intervening transactions. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 20:38 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 5,490 | $10.00 | $54,900.00 |
DisclosureSEC source: 0001104659-17-055821 · a4.xml · nonDerivative · entry 1 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,157 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 20, 2017 Filed Sep 13, 2017 21:23 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 5,490 | $10.00 | $54,900.00 |
DisclosureSEC source: 0001104659-17-056988 · a4.xml · nonDerivative · entry 1 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,413 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: This total reflects the number of shares beneficially owned by the reporting person on July 20, 2017, following the reported transaction. F3 · balance_after: This total reflects an adjustment for a clerical error on the reporting person's Form 3 wherein the number of shares beneficially owned was inadvertently overstated by 62,744 shares. Such shares were sold prior to Dr. Ravina becoming a reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.